Prognostic impact of erythropoietin‐stimulating agent use during front‐line chemotherapy in patients with ovarian cancer: A Korean multicenter cohort study

Abstract

AbstractObjectiveTo evaluate whether treatment with erythropoiesis‐stimulating agents (ESAs) for chemotherapy‐induced anemia affects progression‐free survival (PFS) in patients receiving front‐line chemotherapy following surgery for ovarian cancer (OC).MethodsWe retrospectively reviewed all consecutive patients who received front‐line chemotherapy after surgery between 2013 and 2019 at six institutions. The patients were divided according to the use of ESAs during front‐line chemotherapy. The primary endpoint was PFS. The secondary endpoint was the occurrence of thromboembolism. Propensity score matching (PSM) analysis was used to compare survival between matched cohorts.ResultsOverall, 2147 patients (433 receiving ESA and 1714 for no‐ESA) were identified, with a median follow‐up of 44.0 months. The ESA group showed a significantly higher proportion of stage III/IV disease (81.8% vs 61.1%; P < 0.001) and postoperative gross residual disease (32.3% vs 21.2%; P < 0.001) than the no‐ESA group. In the multivariable Cox regression analysis, the use of ESAs did not affect PFS (adjusted hazard ratio, 1.03; 95% confidence interval [CI]: 0.89–1.20; P = 0.661). The incidence of thromboembolism was 10.2% in the ESA group and 4.6% in the no‐ESA group (adjusted odds ratio, 6.58; 95% CI: 3.26–13.28; P < 0.001). When comparing the well‐matched cohorts after PSM, PFS did not differ between the ESA (median PFS 23.5 months) and no‐ESA groups (median PFS 22.2 months) (P = 0.540, log‐rank test).ConclusionsThe use of ESAs during front‐line chemotherapy did not negatively affect PFS in patients with OC after surgery but increased the risk of thromboembolism.